162 related articles for article (PubMed ID: 34180023)
1. Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation.
Marzuttini F; Mancusi A; Bonato S; Griselli M; Tricarico S; Casarola G; Paradiso M; Ruggeri L; Terenzi A; Merluzzi M; Prigitano A; Tortorano AM; Pitzurra L; Falini B; Carotti A; Velardi A; Pierini A
Ann Hematol; 2021 Sep; 100(9):2375-2380. PubMed ID: 34180023
[TBL] [Abstract][Full Text] [Related]
2. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
4. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
Scott LJ
Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
[TBL] [Abstract][Full Text] [Related]
5. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).
López-Sánchez C; Valcárcel D; Gómez V; López-Jiménez J; Serrano D; Rubio V; Solano C; Vázquez L; Ruiz I;
Rev Esp Quimioter; 2020 Apr; 33(2):110-115. PubMed ID: 32056418
[TBL] [Abstract][Full Text] [Related]
6. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
[TBL] [Abstract][Full Text] [Related]
7. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
8. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.
Tamura K; Drew R
Drugs Today (Barc); 2008 Jul; 44(7):515-30. PubMed ID: 18806902
[TBL] [Abstract][Full Text] [Related]
9. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.
Kimura M; Araoka H; Yamamoto H; Asano-Mori Y; Nakamura S; Yamagoe S; Ohno H; Miyazaki Y; Abe M; Yuasa M; Kaji D; Kageyama K; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Uchida N; Izutsu K; Wake A; Taniguchi S; Yoneyama A
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115352
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplantation Patients.
Gardner JC; Courter JD; Dandoy CE; Davies SM; Teusink-Cross A
Transplant Cell Ther; 2022 Mar; 28(3):167.e1-167.e5. PubMed ID: 34875405
[TBL] [Abstract][Full Text] [Related]
12. Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
Conen A; Weisser M; Jörg CO; Battegay M; Trampuz A; Frei R; Christen S; Heim D; Gratwohl A; Flückiger U
Transpl Infect Dis; 2008 Feb; 10(1):66-70. PubMed ID: 17511816
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis.
Wingen-Heimann SM; Cornely OA; Vehreschild MJGT; Wisplinghoff H; Franke B; Schons M; von Bergwelt-Baildon M; Scheid C; Vehreschild JJ
Mycoses; 2021 Apr; 64(4):437-444. PubMed ID: 33354800
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
15. Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis.
Rothe A; Claßen A; Carney J; Hallek M; Mellinghoff SC; Scheid C; Holtick U; von Bergwelt-Baildon M
Eur J Haematol; 2020 Apr; 104(4):291-298. PubMed ID: 31856310
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
[TBL] [Abstract][Full Text] [Related]
20. Assessment of micafungin dosage regimens against
Wei XC; Zhao MF; Xiao X
J Chemother; 2023 Dec; 35(8):721-729. PubMed ID: 37190751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]